ArticlePeerJ2026
Lactotransferrin upregulation affects the pathological changes of non-small cell lung cancer by regulating ferroptosis.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recent studies have highlighted the role of ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, in cancer biology. This study aims to investigate the effect of lactotransferrin (LTF) upregulation on the pathological changes related to non-small cell lung cancer (NSCLC) Methods: LTF's involvement in NSCLC was investigated through cell experiments and clinical samples. Cell models with stable LTF knockdown or overexpression were established by lentiviral transduction. Cell viability and cytotoxicity were evaluated through cell counting kit 8 (CCK8) and lactate dehydrogenase (LDH) experiments. Scratch and Transwell experiments were conducted to verify the effect of LTF expression on the migration and invasion abilities of lung cancer cells. Protein and mRNA expression were analyzed using Western blotting and qPCR. Malondialdehyde (MDA), glutathione (GSH), free iron ions (Fe Results: The results demonstrate that LTF was upregulated in NSCLC and it's overexpression could significantly enhance the migration, invasion, and epithelial-mesenchymal transition (EMT) of non-small cell lung cancer cells. The overexpression of LTF significantly inhibited ferroptosis in non-small cell lung cancer cells. LTF modulates the expression of critical regulators of ferroptosis including glutathione peroxidase 4 (GPX4) and acyl-CoA synthetase long-chain family member 4 (ACSL4), leading to altered cellular redox status. The protein and mRNA expression levels of LTF were both increased in the peripheral blood of patients with NSCLC, with changes in protein level being more significant. Additionally, the overexpression of LTF was significantly correlated with the stage of NSCLC. Conclusion: In conclusion, these findings suggest that LTF upregulation plays a crucial role in inhibiting ferroptosis, thereby influencing the pathological progression of NSCLC. This study provides a potential therapeutic avenue for targeting ferroptosis in NSCLC treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.